Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,626,172 | 5,745,838 | 4,880,719 | 3,606,314 | 1,716,755 |
| Depreciation Amortization | 2,624,305 | 2,089,510 | 1,838,829 | 1,854,886 | 1,558,750 |
| Accounts receivable | -394,665 | -387,749 | -948,314 | -431,846 | -101,781 |
| Other Working Capital | 658,784 | -341,382 | -39,686 | -1,063,365 | -548,061 |
| Other Operating Activity | 1,221,385 | 168,943 | 1,263,072 | 1,217,854 | 2,636,426 |
| Operating Cash Flow | $8,735,981 | $7,275,160 | $6,994,620 | $5,183,843 | $5,262,089 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,015,075 | -1,089,048 | -1,287,724 | -1,656,207 | -1,337,818 |
| Net Acquisitions | -9,433,243 | -2,370,630 | -250,000 | N/A | -7,923,163 |
| Purchase Of Investment | -805,932 | -248,970 | -923,937 | 535,585 | -2,129,412 |
| Sale Of Investment | 954,361 | 16,306 | 449,231 | 17,830 | 18,476 |
| Other Investing Activity | -1,888,431 | -6,368 | -75,061 | -33,485 | -25,713 |
| Investing Cash Flow | $-12,188,320 | $-3,698,710 | $-2,087,491 | $-1,136,277 | $-11,397,630 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -203,854 | 3,217,331 | -324,739 | -3,603,481 | 5,183,225 |
| Debt Issued | 4,000,000 | 3,000,000 | 0 | 3,500,000 | 4,000,000 |
| Debt Repayment | -1,673,998 | -2,483,176 | -913,948 | -441,012 | -3,532,408 |
| Common Stock Issued | 328,411 | 508,669 | 1,008,843 | 1,249,804 | 502,782 |
| Common Stock Repurchased | -866,825 | -826,345 | -1,081,806 | -1,058,793 | -754,502 |
| Dividend Paid | -2,671,475 | -2,414,460 | -2,174,252 | -1,959,150 | -1,777,170 |
| Financing Cash Flow | $-1,087,741 | $1,002,019 | $-3,485,902 | $-2,312,632 | $3,621,927 |
| Exchange Rate Effect | -620,893 | 118,848 | -115,160 | 200,258 | 73,966 |
| Beginning Cash Position | 8,809,339 | 4,112,022 | 2,456,384 | 521,192 | 2,893,687 |
| End Cash Position | 3,648,371 | 8,809,339 | 4,112,022 | 2,456,384 | 521,192 |
| Net Cash Flow | $-5,160,968 | $4,697,317 | $1,655,638 | $1,935,192 | $-2,372,495 |
| Free Cash Flow | |||||
| Operating Cash Flow | 8,735,981 | 7,275,160 | 6,994,620 | 5,183,843 | 5,262,089 |
| Capital Expenditure | -1,015,075 | -1,089,048 | -1,287,724 | -1,656,207 | -1,337,818 |
| Free Cash Flow | 7,720,906 | 6,186,112 | 5,706,896 | 3,527,636 | 3,924,271 |